Access over 35 million academic & study documents

Pharmacology Question.edited

Content type
User Generated
Showing Page:
Surname 1
Student’s Name
Professor’s Name
GLP-1 Agonists Vs. SGLT2 Inhibitors
Brief Introduction
Type 2 diabetes prevalence is growing at a high rate. In addition, cardiovascular condition
progresses to be the major source of mortality in people suffering from type 2 diabetes (Scheen
89). A lot of the agents used by health care professionals to manage type 2 diabetes have
negative effects such as weight gain and hypoglycemia. Thus, health care professionals have a
primary role in preventing cardiovascular complications and ensuring cardiovascular safety when
selecting the treatment plan for diabetes therapy for type 2 diabetes patients. Fortunately, recent
research has come up with two treatment agents that seem more effective than the other drugs (Li
et al. 1678). GLP-1 and SGLT2 are used in type 2 diabetes patients as therapies to lower glucose.
The two agents mentioned above have additional benefits, such as reduction of blood pressure
and weight loss.
The two drugs above safeguard a patient against major cardiovascular illnesses in
individuals with atherosclerotic cardiovascular condition, alleviate the chances of hospitalization
due to heart failure, and minimize cardiovascular death. When a medical care professional
considers an SGLT2 inhibitor or GLP-1 agonist suitable for therapies of lowering glucose in
patients, they should prioritize the agent based on the existing evidence (Li et al. 1679). Patients

Sign up to view the full document!

lock_open Sign Up
Showing Page: